Survivors Of Childhood Cancers Treated With Cyclophosphamide More Likely To Develop Bladder Cancer Later In Life

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 15 May 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Survivors of childhood cancers treated with the chemotherapy drug cyclophosphamide were five times more likely to develop bladder cancer later in life than the general population. Results of this new research from the United Kingdom were presented during the Annual Scientific Meeting of the American Urological Association (AUA). Survivors originally diagnosed at zero to four years of age and those diagnosed with retinoblastoma, leukemia and non-Hodgkin's lymphoma were at a particularly higher risk.

Researchers will present their findings to the media during a special press conference on May 19, 2008 at 3:00 p.m.

Researchers analyzed British Childhood Cancer Survivor Study (BCCSS) records of patients diagnosed under the age of 15 with leukemia, non-Hodgkin's lymphoma, retinoblastoma or soft tissue sarcoma and subsequently treated with cyclophosphamide or radiotherapy. Patients in the study cohort had a survival rate of at least five years. These data were compared to records from the National Health Service Central Register through 2004 to identify patients who subsequently developed bladder cancer to determine whether treatment choice could be associated with future bladder cancer development.

Bladder cancer was found in 19 patients (5.3 times what was expected), with a mean follow up (post-five-year survival) of 18.9 years. Further analysis of follow-up intervals (20, 30, 40 and 50 years post-five-year survival) indicated that the risk of developing bladder cancer increases with time. The cumulative percentage of survivors diagnosed at 20, 30, 40 and 50 years was 0.02 percent, 0.08 percent, 0.37 percent and 0.71 percent, respectively.

Cyclophosphamide, an immunosuppressive drug used to treat several types of cancer, is known to cause bladder damage that predisposes patients to subsequent bladder cancer.

In addition to the author, Anthony Y. Smith, M.D., a member of the AUA Public Media Committee, will be on hand to provide expert commentary on the studies.

Gurung PM, Leiper A, Woodhouse CRJ, Hawkins MM: Risk of bladder cancer after childhood cancer. J Urol, suppl., 2008; 179: 322, abstract 934.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 15,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs members and their patients, including UrologyHealth.org, an award-winning on-line patient education resource, and the American Urological Association Foundation, Inc.

American Urological Association (AUA)
1000 Corporate Blvd.
Linthicum, MD 21040
United States
http://www.auanet.org